Navigation Links
Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting

sion proteins. These are combinations of vascular targeting agents such as bavituximab and immune system-stimulating cytokines such as interferon and interleukin-2. Peregrine's immunocytokine fusion proteins showed robust anti-tumor efficacy in animal models of melanoma and B-cell lymphoma, without the signs of toxicity that have limited the wide use of cytokines as anti-cancer agents. In particular, the 85% reduction in tumor growth observed in the B-cell lymphoma model serves as an important validation of Peregrine's VTA immunocytokine approach, and hematological cancers such as lymphoma also represent potential new cancer indications for the company.

Data on Peregrine's VTA coaguligand and VEA anti-cancer development programs.

Researchers working with Peregrine presented data on progress in the company's VTA coaguligand development program, its VEA program and its initiatives to develop second-generation anti-PS monoclonal antibodies.

    *  Peregrine's VTA coaguligands program has developed fusion proteins that

       combine a vascular targeting antibody with modified tissue factor, a

       protein that can induce blocking and destruction of targeted blood

       vessels.  Since Peregrine's VTAs specifically target tumor blood

       vessels, the fusion proteins are intended to affect only the

       established blood vessels that are essential for the survival and

       growth of tumors.  Researchers reported on their progress in

       successfully developing and testing a series of VTA coaguligands that

       currently are in further testing in animal cancer models.


    *  Peregrine researchers gave an oral presentation on novel methods the

       company is employing in its drug discovery efforts for its VEA program.

       VEAs are a new class of therapeutics comprised of tumor-specific

       antibodies fused to vasoactive compound
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
4. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
5. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
(Date:8/4/2015)... 04, 2015 Research ... addition of Jain PharmaBiotech,s new report "Animal ... their offering. This report describes and ... medicine and pharmaceuticals as well as improvement in ... in the application of biotechnology to manage genetic ...
(Date:8/4/2015)... Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ) today reported ... June 30, 2015 and updated its financial guidance for ... this morning, August 4, 2015, at 10:30 AM ET. ... by dialing (855) 582-8078. The conference ID is 90889796. ... revenues of $38.3 million, an increase of 118% as compared ...
Breaking Medicine Technology:Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 2Animal Biotechnology 2014-2024 - 2015 Technologies, Markets and Companies Analysis 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 4ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 5ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 6ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 7ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 8ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 9ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 10ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 11ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 12ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 13ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 14ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 15ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 16
... Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company ... therapeutic agents for the treatment of Alzheimer,s and ... filed a response and request for continued examination ... 10/084,380, one of several applications pending in the ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... chief financial officer, will present an overview of the ... The VIVUS presentation will take place at the ... at 9:30 a.m. MST.  A live webcast and 30-day ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard to look your ... Spa in Santa Barbara, CA is offering the solution by offering an underarm ... sweat and odor glands in the underarms. This simple and permanent solution usually ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... Kingdom and other international locations have shown a rise in binge drinking among ... link between binge drinking and depression, are continuing to examine trends and evidence ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... They say ... better understand certain health conditions, pictures and medical art can be essential. StayWell, a ... providers. , Krames Patient Education solutions have been used by physicians and other ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... that Bruce McCalley joins its executive leadership team as Senior Vice President of ... at technology companies and expanding global markets with a special emphasis on the ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... nursing homes and other long-term care facilities, today announced details of the Advanced ... nursing homes and centers. , Providigm’s QAPI Accreditation program , introduced in ...
Breaking Medicine News(10 mins):Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3
... with thousands of,herb-loving individuals, organizations and businesses across ... tomorrow, Oct. 13. The company will,continue to celebrate ... free 28-ct Mega Men(R) or Women,s Ultra Mega(R) ... National Herb Day recognizes the importance of ...
... the solution to providing ... STORRS, Conn., Oct. 12 A new report released,today ... low health,literacy to the United States economy is in the ... report, Low Health Literacy:,Implications for National Health Policy, the savings ...
... (Nasdaq: ARAY ), a global leader in the ... for its first quarter fiscal,year 2008, ending September 29, ... A conference call to review the results will ... be hosted by Euan S. Thomson, Ph.D., president and,chief ...
... might fight deadly pulmonary disease, experts say , , FRIDAY, Oct. ... cholesterol also slow the lung function loss that inevitably occurs ... researchers report. , The Harvard study included a group of ... at least twice between 1995 and 2005. , Those who ...
... be good for lowering cholesterol and maybe even fighting ... appear to slow decline in lung function in the ... in Boston, it may be statins anti-inflammatory and antioxidant ... were published in the second issue for October in ...
... Feeds the Soul and Whets the Appetite, RALEIGH, ... this weight-loss support group turned relay team, wondered what,their ... would be. Maria,Fernandez and the members of TeamGDT thought ... for the Cure", was a great answer,to not only ...
Cached Medicine News:Health News:GNC Honors Herb Day Tomorrow (and All Month Long) 2Health News:New Report Estimates Cost of Low Health Literacy Between $106 - $236 Billion Annually 2Health News:New Report Estimates Cost of Low Health Literacy Between $106 - $236 Billion Annually 3Health News:Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results 2Health News:Anti-Cholesterol Drugs Help Prevent Lung Decline 2Health News:Statins reduce loss of function, keeping old lungs young - even in smokers 2Health News:Good Food. Good Friends. Great Cause. 2
... Sirolimus-eluting Coronary Stent consists of ... "sirolimus", a controlled-release polymer, and ... Upon placement, sirolimus elutes into ... the process of neointimal hyperplasia, ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support....
Forte Guide Wire w/Markers: Front line use, 1:1 torque, excellent steering and tracking, sharp vessel images, floppy and moderate support....
Medicine Products: